

Table 1. Overview of TEAEs and most common TEAEs (occurring in $\geq 15\%$ of patients in any group) in Japanese patients (Safety Analysis Set)

	Number of baseline ASMs			Most common baseline ASMs					
	1 (n=7)	2 (n=29)	3 (n=29)	Valproic acid (n=26)	Levetiracetam (n=23)	Lamotrigine (n=21)	Clobazam (n=20)	Topiramate (n=11)	Carbamazepine (n=10)
Any TEAE, n (%)	6 (85.7)	27 (93.1)	27 (93.1)	23 (88.5)	23 (100.0)	19 (90.5)	19 (95.0)	10 (90.9)	9 (90.0)
Nasopharyngitis	3 (42.9)	3 (10.3)	15 (51.7)	8 (30.8)	9 (39.1)	5 (23.8)	9 (45.0)	4 (36.4)	2 (20.0)
Somnolence	2 (28.6)	9 (31.0)	7 (24.1)	8 (30.8)	6 (26.1)	4 (19.0)	9 (45.0)	2 (18.2)	3 (30.0)
Influenza	2 (28.6)	8 (27.6)	7 (24.1)	5 (19.2)	6 (26.1)	7 (33.3)	5 (25.0)	4 (36.4)	4 (40.0)
Upper respiratory tract infection	2 (28.6)	7 (24.1)	5 (17.2)	7 (26.9)	4 (17.4)	4 (19.0)	3 (15.0)	3 (27.3)	3 (30.0)
Irritability	2 (28.6)	4 (13.8)	6 (20.7)	6 (23.1)	4 (17.4)	5 (23.8)	2 (10.0)	1 (9.1)	1 (10.0)
Dizziness	0 (0.0)	6 (20.7)	5 (17.2)	8 (30.8)	3 (13.0)	7 (33.3)	3 (15.0)	1 (9.1)	1 (10.0)
Pyrexia	1 (14.3)	4 (13.8)	4 (13.8)	2 (7.7)	3 (13.0)	3 (14.3)	2 (10.0)	0 (0.0)	2 (20.0)
Vomiting	3 (42.9)	2 (6.9)	2 (6.9)	0 (0.0)	3 (13.0)	2 (9.5)	0 (0.0)	0 (0.0)	1 (10.0)
Gastroenteritis	2 (28.6)	2 (6.9)	2 (6.9)	1 (3.8)	2 (8.7)	2 (9.5)	1 (5.0)	1 (9.1)	1 (10.0)
Upper respiratory tract inflammation	0 (0.0)	2 (6.9)	3 (10.3)	1 (3.8)	1 (4.3)	1 (4.8)	1 (5.0)	1 (9.1)	2 (20.0)
Urinary incontinence	0 (0.0)	2 (6.9)	1 (3.4)	2 (7.7)	0 (0.0)	1 (4.8)	2 (10.0)	2 (18.2)	0 (0.0)
Eczema	0 (0.0)	2 (6.9)	0 (0.0)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (20.0)

Patients with ≥ 2 TEAEs in the same system organ class (or with the same preferred term) are counted only once for that system organ class or

preferred term. ASM, anti-seizure medication; TEAE, treatment-emergent adverse event